Exabis Library
Welcome to the e-CCO Library!
DOP41: Low grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century – a large multi-centre retrospective cohort study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP41: Mucosal single-cell profiling of Crohn's-like disease of the pouch reveal unique pathogenesis and therapeutic targets
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP41: Temporal Trends in the epidemiology of Inflammatory Bowel Diseases in the public healthcare system in Brazil: A large population-based study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP42 Impact of discontinuing thiopurines at anti-TNF initiation in inflammatory bowel disease: A nationwide Danish cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP42: Dietary therapies induce rapid response and remission in active paediatric Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP42: Dietary Therapies Induce Rapid Response and Remission in Active Paediatric Crohn’s Disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP42: Disease course and clinical outcomes in Taiwan Crohn’s Disease patients with perianal fistula: A nationwide-based study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP42: Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP42: Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP42: Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP42: Impact of discontinuing thiopurines at anti-TNF initiation in Inflammatory Bowel Disease: A nationwide Danish cohort study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP42: Impact of discontinuing thiopurines at anti-TNF initiation in Inflammatory Bowel Disease: A nationwide Danish cohort study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP43 The risk of extra-intestinal cancer in inflammatory bowel disease (IBD): A systematic review and meta-analysis of population-based cohort studies
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP43: Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP43: Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP43: Histologic improvement, attenuation of inflammation and microbiome modulation by engineered high acetate producing Saccharomyces boulardii in DSS-induced colitis
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP43: Impact of Inflammatory Bowel Diseases on the phenotype and severity of psoriasis and spondyloarthropathies
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: Results of the OCTAVE Open study for tofacitinib delayed responders
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP43: Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM